Helus Pharma Inc. Common Stock

HELP

Capitalización de mercado USD 771 M

This news release constitutes a “designated news release” for the purpose of the Company's prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025.

Helus Pharma remains a buy, as HLP003's Phase 3 APPROACH topline data in 4Q26 is the key near-term catalyst. HLP003 targets adjunctive MDD with a differentiated intermittent dosing model; prior Phase 2 data showed a 23-point MADRS reduction and 71% remission at 12 months. HELP's $166.4M cash balance provides 12–14 months runway, but dilution risk persists given high operating outflows and the $100M ATM facility.

NEW YORK and TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce that the Company will host an investor presentation on October 21, 2026.

NEW YORK and TORONTO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the Company's legal name has been changed from “Cybin Inc.” to “Helus Pharma Inc.” effective October 1, 2026. The name change was approved by shareholders at the Company's annual and special meeting of shareholders held on September 22, 2026.

Helus Pharma, formerly known as Cybin NASDAQ: HELP, outlined its late-stage development plans for HLP-003 in adjunctive major depressive disorder (MDD) and discussed its broader pipeline of serotonergic agonists during TD Cowen's Novel Mechanisms in Neuropsychiatry virtual summit.

TORONTO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the voting results for each of the matters presented at the Company's annual and special meeting of shareholders held on September 22, 2026 (the “Meeting”). There were 107 shareholders represented in person or by proxy at the Meeting holding 46,452,598 common shares, representing 63.58% of Helus's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are set out below.

Cybin Inc. (HELP) Shareholder/Analyst Call Prepared Remarks Transcript

Cybin NASDAQ: HELP, doing business as Helus Pharma, held its Annual General and Special Meeting of Shareholders, where shareholders were asked to consider resolutions related to the company's auditor, board size, corporate name and director elections.

CEO Michael Halstead to participate in a fireside chat on September 23, 2026 at 9:00 a.m. EDT CEO Michael Halstead to participate in a fireside chat on September 23, 2026 at 9:00 a.m. EDT

Poster presentations further characterize clinical profile of HLP003 and  Phase 3 PARADIGM program evaluating HLP003 as a potential adjunctive treatment for major depressive disorder (“MDD”) NEW YORK and TORONTO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced the presentation of four posters evaluating HLP003, an investigational oral deuterated psilocin analog being developed as an adjunctive treatment for MDD, at Psych Congress 2026, September 15–19, 2026, at the Ernest N.